HUAWEI
26.3.2019 17:06:04 CET | Business Wire | Press release
During an exclusive launch event today at the Paris Convention Center, Huawei Consumer Business Group (BG) unveiled the HUAWEI P30 and HUAWEI P30 Pro. The HUAWEI P30 Series builds on the HUAWEI P Series DNA in design and photography and is the company’s most advanced series of smartphone cameras. These devices feature the innovative HUAWEI SuperSpectrum Sensor, an optical SuperZoom Lens, a new HUAWEI Time of Flight (ToF) Camera, and enhanced optical and AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro capture incredible photos and videos in every scenario.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005752/en/
Richard Yu, CEO of Huawei Consumer BG, said, “the HUAWEI P30 Series is a fundamental breakthrough after decades of digital camera technology development; it will rewrite the rules and reshape everyone’s perception of mobile photography. Innovations such as the HUAWEI SuperSpectrum Sensor and SuperZoom Lens allow us to push the envelope of both photography and videography—a frontier long overdue for disruption. The HUAWEI P30 Series will set the pace for the next generation of smartphones by empowering people to capture the true beauty of the world around them through a device that fits in the palm of their hands.”
Rewriting the Rules of Photography for Stunning Professional-grade Pictures Every Time
Achieving a record-high overall DxOMark score of 112, the HUAWEI P30 Pro is equipped with a new Leica Quad Camera System, including a 40MP main camera with the HUAWEI SuperSpectrum Sensor, a 20MP ultra-wide angle camera, an 8MP telephoto camera, the HUAWEI ToF Camera and a 32MP front camera that takes selfies to a new level.
The 1/1.7-inch HUAWEI SuperSpectrum Sensor looks at light in a fundamentally new way. The RYYB HUAWEI SuperSpectrum Sensor deviates from the traditional RGGB Bayer filter by replacing green pixels with yellow pixels, yielding a high maximum ISO rating of 409,600 on the HUAWEI P30 Pro and 204,800 on the HUAWEI P30. This fundamental shift in sensor technology, combined with HUAWEI AIS, OIS and the HUAWEI P30 Pro’s f/1.6 wide aperture, delivers extraordinary photography and videography experiences across a wide range of scenarios and lighting conditions—including extreme low light—producing images with enhanced detail, color and clarity.
Through a new periscope design, the SuperZoom Lens supports high fidelity magnification of 5 times optical zoom, 10 times hybrid zoom and 50 times digital zoom. A prism element in the telephoto camera bends light at a 90-degree angle to maximize focal length while minimizing camera height, without disrupting device design.
Unique to the HUAWEI P30 Pro is a HUAWEI ToF Camera that captures depth-of-field information to deliver accurate image segmentation. Precise distance measurement allows for the simulation of multiple levels of bokeh. The Super Portrait feature captures even the smallest details, such as individual strands of hair. It combines depth information and proprietary algorithms to produce outstanding images with defocused backgrounds and highlights the subject of the image in any scenario.
Redefining Smartphone Videography
The HUAWEI SuperSpectrum Sensor enables spectacular low-light video capture so night scenes appear bright and highly detailed. HUAWEI AIS and OIS support stabilization for all video capture settings, resulting in a perfect, steady shot. Additionally, the SuperZoom Lens allows for crisp close-ups, while the AI Video Editor enables users to add background music and special effects to their videos, turning the HUAWEI P30 Series into a mobile production studio.
A Heritage of Stunning Design
The HUAWEI P30 Series design, created with a nine-layer nano optical color finish, is inspired by the unique color palette and pristine look of salt flats. The 6.47-inch HUAWEI P30 Pro and 6.1-inch HUAWEI P30 come in Breathing Crystal, Amber Sunrise, Aurora, Pearl White and Black. The FHD+ (2340x1080) Dewdrop Display features a tiny notch, providing maximum display area. The near bezel-less front glass houses an In-Screen Fingerprint sensor for quick and secure identity authentication. The HUAWEI P30 Pro also features HUAWEI Acoustic Display Technology that enables it to deliver high-quality audio through a sound emitting display.
Ultimate Innovation
The HUAWEI P30 and HUAWEI P30 Pro are packed with industry-leading features that set them apart in power, performance and efficiency:
- The HUAWEI P30 Series is powered by the 7nm Kirin 980 processor, which delivers ultimate performance, top-class efficiency and faster image recognition through its Dual-NPU AI processing power.
- The HUAWEI P30 Series features an Extendable Read-Only File System that improves system responsiveness. The latest EMUI 9.1 also supports HUAWEI Share OneHop for seamless file sharing between Huawei smartphones and Huawei laptops.
- The HUAWEI P30 Pro features a 4200mAh battery (typical value) and 40W HUAWEI SuperCharge that charges a device from zero to 70 percent in 30 minutes, keeping the device powered for more than a full day of intensive work.
- The HUAWEI P30 Pro features HUAWEI SuperCool technology to improve thermal performance, keeping the phone cool even during heavy use.
- The HUAWEI P30 Series is equipped with a suite of advanced wireless communications capabilities supporting Dual SIM and Dual VoLTE connectivity1 .
Pricing and Availability
Starting at EUR 799 and EUR 999 respectively, the new HUAWEI P30 and HUAWEI P30 Pro are immediately available globally.
About Huawei Consumer BG
Huawei’s products and services are
available in more than 170 countries and are used by a third of the
world’s population. Fifteen R&D centers have been set up in the United
States, Germany, Sweden, Russia, India and China. Huawei Consumer BG is
one of Huawei’s three business units and covers smartphones, PC and
tablets, wearables and cloud services, etc. Huawei’s global network is
built on almost 30 years of expertise in the telecom industry and is
dedicated to delivering the latest technological advances to consumers
around the world.
1 Specific features may vary depending on regional availability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190326005752/en/
Contact:
Mark Fowler +44 (0)208 811 2474 Huawei@racepointglobal.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom